Question 1

What is 4basebio?

Accepted Answer

4basebio is a Company.

Question 2

How often does 4basebio appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was 4basebio first tracked by Ergen?

Accepted Answer

First tracked on May 20, 2026.

Question 4

When was 4basebio last mentioned in news?

Accepted Answer

Last active on Jun 15, 2026.

Question 5

What is 4basebio's current news sentiment?

Accepted Answer

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is 4basebio in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving 4basebio?

Accepted Answer

4basebio Signs Clinical Supply Agreement (May 20, 2026, 6 articles).

Question 8

How did the "4basebio Signs Clinical Supply Agreement" event impact 4basebio?

Accepted Answer

4basebio signed a Clinical Supply Agreement to provide GMP-grade opDNA for a Phase II clinical trial, securing a seven-figure revenue stream and demonstrating the commercial momentum of its technology.

Question 9

How did the "4basebio Appoints Jeff Coller" event impact 4basebio?

Accepted Answer

4basebio appointed Jeff Coller to its Strategic Advisory Board, which is expected to enhance its synthetic DNA and mRNA manufacturing capabilities and strategic direction.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.